ASH 2023 | VEN-AZA versus intensive chemotherapy as bridging therapy in patients with MDS
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, presents findings from a retrospective real-world study comparing outcomes of bridging therapy for patients with myelodysplastic syndromes (MDS) treated with venetoclax and azacitidine (VEN-AZA) versus intensive chemotherapy. The study reveals comparable remission rates, bridging to transplant rates, and overall survival (OS) between the two groups. Notably, VEN-AZA demonstrates lower toxicity rates, especially in older and less fit patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Astellas, Pfizer, Novartis, Janssen
Honoraria: Abbvie, Astellas, Novartis, Janssen
Travel Expenses: Abbvie, Novartis, Janssen, Takeda
